CO2023011969A2 - Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos - Google Patents

Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos

Info

Publication number
CO2023011969A2
CO2023011969A2 CONC2023/0011969A CO2023011969A CO2023011969A2 CO 2023011969 A2 CO2023011969 A2 CO 2023011969A2 CO 2023011969 A CO2023011969 A CO 2023011969A CO 2023011969 A2 CO2023011969 A2 CO 2023011969A2
Authority
CO
Colombia
Prior art keywords
tl1a
compositions
ligands
antibodies against
humanized antibodies
Prior art date
Application number
CONC2023/0011969A
Other languages
English (en)
Inventor
Janine Bilsborough
Bradley Henkle
Stephan R Targan
Olivier Laurent
Allison Luo
Lauren Otsuki
Mark Manning
Robert Payne
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of CO2023011969A2 publication Critical patent/CO2023011969A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento, se describen anticuerpos humanizados anti-TL1A y composiciones farmacéuticas para el tratamiento de enfermedades inflamatorias intestinales (IBD), tales como la enfermedad de Crohn (CD) y colitis ulcerosa (UC).
CONC2023/0011969A 2021-02-18 2023-09-08 Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos CO2023011969A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US202163285781P 2021-12-03 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (1)

Publication Number Publication Date
CO2023011969A2 true CO2023011969A2 (es) 2023-09-29

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0011969A CO2023011969A2 (es) 2021-02-18 2023-09-08 Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos

Country Status (16)

Country Link
EP (1) EP4294444A1 (es)
JP (1) JP2024506940A (es)
KR (1) KR20230157973A (es)
AU (1) AU2022223420A1 (es)
BR (1) BR112023016672A2 (es)
CA (1) CA3207817A1 (es)
CL (1) CL2023002424A1 (es)
CO (1) CO2023011969A2 (es)
CR (1) CR20230436A (es)
DO (1) DOP2023000162A (es)
EC (1) ECSP23070237A (es)
IL (1) IL305312A (es)
MX (1) MX2023009622A (es)
PE (1) PE20231681A1 (es)
TW (1) TW202246322A (es)
WO (1) WO2022178159A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SG11201602671WA (en) * 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
CA3098374A1 (en) * 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies

Also Published As

Publication number Publication date
WO2022178159A1 (en) 2022-08-25
MX2023009622A (es) 2023-08-28
PE20231681A1 (es) 2023-10-19
BR112023016672A2 (pt) 2023-11-21
CL2023002424A1 (es) 2024-01-05
JP2024506940A (ja) 2024-02-15
CR20230436A (es) 2023-11-01
KR20230157973A (ko) 2023-11-17
CA3207817A1 (en) 2022-08-25
AU2022223420A1 (en) 2023-09-21
DOP2023000162A (es) 2023-10-15
IL305312A (en) 2023-10-01
ECSP23070237A (es) 2023-10-31
TW202246322A (zh) 2022-12-01
EP4294444A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
CL2022001016A1 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
CO2022006679A2 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
CO2023011969A2 (es) Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos
CO2020015172A2 (es) Anticuerpos biespecíficos contra dll3-cd3
CO2023011962A2 (es) Anticuerpos anti-cd30l y usos de estos
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
BR112017024264A2 (pt) ?composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para suaadministração?
BR112018076327A2 (pt) compostos como inibidores de autotaxinas e composições farmacêuticas compreendendo os mesmos
EA201892790A1 (ru) Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
UY33715A (es) Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a)
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
ECSP15038626A (es) A61k 30/395
WO2019209995A3 (en) Optimized anti-tl1a antibodies
MX2020008502A (es) Dosis para el tratamiento con proteinas de fusion il-22 fc.
UY38293A (es) Nuevos compuestos y composiciones de c-manósido antagonistas de fimh
AR117950A1 (es) Receptores quiméricos de steap1 y composición farmacéutica que los contienen
BR112017002333A2 (pt) anticorpo ou um fragmento de ligação ao antígeno do anticorpo, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira transformada, e, método para produzir um anticorpo ou um fragmento de ligação ao antígeno do anticorpo.
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
CL2021002735A1 (es) Anticuerpos anti-pd-l1 modificados y métodos y usos para el tratamiento de una enfermedad neurodegenerativa
BR112022019958A2 (pt) Composições e métodos para o tratamento de doenças inflamatórias do intestino utilizando anticorpos inibidores de ccr9 e anticorpos de bloqueio anti-il -23
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
CL2017000988A1 (es) Proceso de síntesis de hidroxi-triacilgliceroles y usos de los mismos para la prevención y el tratamiento de enfermedades
MD4474B1 (ro) Mediu de protecţie pentru liofilizarea şi păstrarea îndelungată a tulpinii Streptomyces canosus CNMN-Ac-02